KalVista CDO sells 33,800 shares after option exercise

KalVista Pharmaceuticals chief development officer Christopher Yea reported an option exercise paired with an open-market sale of common stock.

Rhea-AI Filing Summary

KalVista Pharmaceuticals chief development officer Christopher Yea reported an option exercise paired with an open-market sale of common stock. He exercised employee stock options to acquire 33,800 shares at an exercise price of $7.07 per share, fully exercising that option grant. On the same date, he sold 33,800 common shares in open-market transactions at a weighted average price of $26.7818 per share, with individual trades ranging from $26.78 to $26.79. Following these transactions, Yea directly owns 229,918 shares of KalVista common stock.

Insider Trade Summary

Exercise and Sale: 33,800 shares ($666K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Yea Christopher

Role CHIEF DEVELOPMENT OFFICER

Sold 33,800 shs ($905K)

Approx. gross sale proceeds $905K

Approx. exercise cost $239K

Approx. pre-tax spread $666K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Buy)	33,800	$0.00	$0.00
Exercise	Common Stock	33,800	$7.07	$239K
Sale	Common Stock	33,800	$26.7818	$905K

Holdings After Transaction: Employee Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 229,918 shares (Direct)

Footnotes (2)

1. F1. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.78 to $26.79 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. F2. This option is 100% vested and exercised.

Key Figures

Shares sold: 33,800 shares Weighted average sale price: $26.7818 per share Option exercise price: $7.07 per share +1 more

4 metrics

Shares sold 33,800 shares Open-market sale of KalVista common stock on 2026-05-27

Weighted average sale price $26.7818 per share Multiple sale transactions between $26.78 and $26.79

Option exercise price $7.07 per share Employee stock option for 33,800 shares, fully exercised

Shares owned after transactions 229,918 shares Direct KalVista common stock holdings following reported trades

Key Terms

weighted average price, Employee Stock Option (Right to Buy), derivative security

3 terms

weighted average price financial

"The reported price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Employee Stock Option (Right to Buy) financial

"security_title: "Employee Stock Option (Right to Buy)""

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KalVista (KALV) report for Christopher Yea?

KalVista’s chief development officer Christopher Yea reported an option exercise and matching share sale. He exercised options for 33,800 common shares, then sold 33,800 shares in open-market transactions on the same date, updating his direct ownership position.

How many KalVista (KALV) shares did Christopher Yea sell and at what price?

Christopher Yea sold 33,800 KalVista common shares in the open market. The weighted average sale price was $26.7818 per share, with individual trades executed between $26.78 and $26.79 per share, according to the reported weighted average footnote.

What stock options did Christopher Yea exercise at KalVista (KALV)?

Christopher Yea exercised employee stock options covering 33,800 shares of KalVista common stock. These options had an exercise price of $7.07 per share, and the related footnote states the option is 100% vested and exercised, leaving no remaining balance under that grant.

How many KalVista (KALV) shares does Christopher Yea own after this Form 4?

After the reported transactions, Christopher Yea directly owns 229,918 KalVista common shares. This figure reflects his holdings following the exercise of 33,800 options and the sale of 33,800 shares in open-market transactions on the reported transaction date.

Was Christopher Yea’s KalVista (KALV) sale a weighted average transaction?

Yes. The filing notes the reported sale price is a weighted average. The 33,800 shares were sold in multiple transactions, with individual prices ranging from $26.78 to $26.79 per share, and a weighted average sale price of $26.7818 per share.

Did Christopher Yea fully exercise a KalVista (KALV) stock option grant?

Yes. The Form 4 shows an employee stock option for 33,800 shares with a $7.07 exercise price. A footnote states this option is 100% vested and exercised, and the derivative position shows zero remaining options following the exercise transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yea Christopher

(Last) (First) (Middle)

C/O KALVISTA PHARMACEUTICALS, INC.

200 CROSSING BOULEVARD

(Street)

FRAMINGHAM MASSACHUSETTS 01702

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KalVista Pharmaceuticals, Inc. [ KALV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF DEVELOPMENT OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/27/2026		M		33,800	A	$7.07	263,718	D
Common Stock	05/27/2026		S		33,800	D	$26.7818(1)	229,918	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$7.07	05/27/2026		M			33,800	(2)	05/24/2027	Common Stock	33,800	$0	0	D

Explanation of Responses:

1. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.78 to $26.79 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. This option is 100% vested and exercised.

	/s/ Benjamin L. Palleiko, Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)